A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer
NMIBC
Carcinoma in Situ of Bladder
Bladder Cancer
Urothelial Carcinoma Bladder
Urothelial Carcinoma Recurrent

Interventions

DRUG: UGN-301
DRUG: UGN-201
DRUG: Gemcitabine

Sponsor

UroGen Pharma Ltd.